CorMedix Inc.

CRMD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $144.8M $40.7M $43.6M $43.1M $53.3M $41.9M $16.4M $17.6M
Accounts Receivable $171.2M $51.7M — — — — — $10.9K
Inventory $29.7M $7.6M $2.1M — $3.0K $143.6K $338.5K $428.5K
Total Current Assets $367.1M $114.6M $79.5M $59.6M $66.5M $48.2M $29.3M $18.7M
Property, Plant & Equipment $6.0M $1.8M $1.9M $1.6M $1.5M $111.5K $122.1K $160.9K
Goodwill $30.0M — — — — — — —
Intangible Assets (Excl. Goodwill) $379.1M $1.8M — — — — — —
Total Assets $826.1M $118.8M $82.1M $62.0M $68.9M $49.3M $29.5M $18.8M
Liabilities
Accounts Payable $7.9M $1.7M $4.3M $2.2M $2.2M $1.1M $1.0M $2.6M
Total Current Liabilities $174.3M $33.8M $11.4M $6.3M $5.3M $4.2M $5.8M $7.8M
Long-Term Debt — — — — — — — —
Total Liabilities $420.8M $34.2M $11.9M $7.0M $6.1M $5.1M $5.8M $13.9M
Stockholders' Equity
Retained Earnings $-176.6M $-339.6M $-321.7M $-275.4M $-245.7M $-217.4M $-195.4M $-179.0M
Total Stockholders' Equity $405.3M $84.7M $70.1M $55.1M $62.8M $44.2M $23.6M $4.9M
← Newer Page 1 of 2 Older →